CICC: Maintain outperform rating on Kangji Medical Company (00867.HK), raise target price to HK$15.40.

According to the Wise Finance APP, Zhongjin released a research report stating that it maintains its profit forecast for Konzern pharmaceutical industry (00867.HK) in 2025 and 2026 unchanged. The current stock price corresponds to a price-to-earnings ratio of 17.3 times / 15.6 times in 2025/2026. The bank maintains an outperform rating, considering the upward trend in sector valuation and good progress in the German magnesium business. The bank has raised its target price by 40% to HK$15.40, corresponding to a price-to-earnings ratio of 19.8 times in 2025 and 18.0 times in 2026, with a 14.9% upside potential compared to the current stock price.